Tandem Diabetes (TNDM) Misses Q1 EPS by 23c, Beats on Revenues; Offers FY18 Revenue Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Burry doubles down on Nebius short after stock surges 34% on earnings
- Total darkness, then sunset as full eclipse wows spectators in Spain
Tandem Diabetes Care (TNDM) PT Raised to $7.50 at Stifel
April 27, 2018 10:32 AM EDTStifel raised its price target on Tandem Diabetes Care (NASDAQ: TNDM) to $7.50 while maintaining a Hold rating.
... MoreTandem Diabetes Care (TNDM) PT Raised to $9 at Cowen; More Upside
April 27, 2018 7:48 AM EDTCowen raised its price target on Tandem Diabetes Care (NASDAQ: TNDM) to $9.00 (from $7.00) while maintaining a Outperform rating.
Analyst Doug Schenkel commented, "TNDM posted a solid Q1 beat. We expect numerous revenue growth catalysts (new products, renewals, Animas, international, infusion sets) to drive upside to... More
